Accord Healthcare: First oral treatment for hormone-sensitive prostate cancer recommended by NICE

Today, Accord Healthcare has announced that the National Institute for Health and Care excellence (NICE) have recommended the first oral androgen deprivation therapy (ADT) treatment for hormone-sensitive prostate cancer. Prostate cancer is the most common cancer in men across the UK. The post First oral treatment for hormone-sensitive prostate cancer recommended by NICE appeared first on Pharmafile.